GLP-1 and metabolic medicine
Prescription medicine

Tirzepatide

A once-weekly dual GIP and GLP-1 receptor agonist used under different brand names for type 2 diabetes and weight management, depending on country and indication.

Educational information only. This guide does not diagnose, prescribe, recommend a product or provide a personal dose. Use the official leaflet supplied with your exact medicine and follow your clinician's plan.

What is Tirzepatide?

Tirzepatide is a synthetic peptide medicine that activates two incretin pathways. Brand, indication and eligibility differ between markets, so the active ingredient should not be confused with a single universal product approval.

Approved-use context

Regulators have authorised tirzepatide products for specified adults with type 2 diabetes and, under separate product authorisations in some markets, chronic weight management. It is not suitable for everyone and requires a prescription and clinical assessment.

How it works

Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. These pathways influence glucose-dependent insulin release, glucagon signalling, gastric emptying, appetite and food intake.

Formulations and schedules

Commercial products are supplied in pre-filled injection devices for subcutaneous use. Device instructions, strengths and authorised uses are product- and market-specific; users should follow their own product leaflet and clinical plan.

Useful information to track

  • Administration date and time
  • Weight trend where clinically relevant
  • Appetite and gastrointestinal symptoms
  • Blood-glucose information requested by a clinician
  • Questions to raise at the next clinical review

Important safety considerations

  • Nausea, diarrhoea, vomiting and constipation are commonly reported
  • Dehydration can become important when gastrointestinal symptoms are persistent
  • Hypoglycaemia risk can increase when combined with insulin or some diabetes medicines
  • Severe or persistent abdominal symptoms require prompt clinical advice
  • Pregnancy, other medicines and relevant medical history should be discussed with the prescriber

Questions for a clinician or pharmacist

  • Which authorised product and indication applies to me?
  • What symptoms should prompt urgent advice?
  • How should I handle a missed administration?
  • What monitoring does my clinician want recorded?

Authoritative references

Regulatory status, warnings and availability can change. Check the current official product information for your country.